Safety Evaluation of Pueraria Lobata Radix in Specific Consumption Scenarios for Type 2 Diabetes

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorJiangxi University of Traditional Chinese Medicine

About this trial

This real-world study aims to investigate the association between the consumption of Pueraria lobata radix and adverse events in patients with type 2 diabetes mellitus (T2DM) under special scenarios. By retrospectively analyzing the clinical data of patients with T2DM, we will evaluate the safety profile of Pueraria lobata radix in different special populations, identify potential risk factors, and provide evidence-based support for the safe consumption and clinical use of Pueraria lobata radix.

Eligibility criteria

Qualifiers

Diagnosis with T2DM.

Documented history of consuming Pueraria lobata radix (PLR) in any dosage form (e.g., dried slices, root cubes).

Fulfillment of at least one of the following special scenarios: 1) Excessive dosage: Daily PLR intake ≥ twice the maximum dose specified in the Chinese Pharmacopoeia; 2) Long-term consumption: PLR consumption duration ≥ three months with frequency ≥ three times weekly; 3) Advanced age: ≥ 80 years; 4) Pregnancy; 5) Lactation; 6) Allergic constitution: History of any food or drug allergy; 7) Liver dysfunction: Clinical diagnosis of liver cirrhosis or chronic liver failure, or laboratory findings of total bilirubin > 1.5 × upper limit of normal (ULN) or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 2 × ULN; 8) Renal insufficiency: Clinical diagnosis of diabetic nephropathy or chronic nephritis with renal function impairment, or serum creatinine > 120% of ULN.

Occurrence of adverse events during the retrospective observation period within one month following PLR consumption.

Disqualifiers

Diagnosis of type 1 diabetes mellitus, gestational diabetes mellitus, or other specific types of diabetes.

Use of PLR compound preparations (e.g., puerarin injection).

Unavailability of complete clinical data or patient refusal to provide essential information required for the observation period during follow-up.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

500 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Jiangxi University of Traditional Chinese Medicine

Lead sponsor

The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine

Collaborator